Table 1.

Median CRP (mg/L) and interquartile range by region (Europe/ANZ versus Japan) and patient characteristics

Patient Characteristicsa,bEurope/ANZ (n = 3194)Japan (n = 1392)
PercentCRP Median (IQR)PercentCRP Median (IQR)
Overall100%6.0 (3.0 to 14.0)100%1.0 (0.5 to 3.1)
Sex
    female40.3%5.6 (3.0 to 12.1)40.2%1.0 (0.4 to 3.0)
    male59.7%7.0 (3.1 to 15.0)59.8%1.3 (0.7 to 4.0)
Age (years)
    18 to 5423.9%5.0 (3.0 to 11.0)21.0%1.0 (0.5 to 2.5)
    54 to 6419.7%6.0 (3.0 to 13.0)31.7%1.1 (0.5 to 3.0)
    65 to 7427.8%6.6 (3.1 to 14.8)27.2%1.1 (0.5 to 3.1)
    ≥ 7528.7%7.0 (4.0 to 16.0)20.0%1.4 (0.6 to 4.1)
Time on ESRD
    <1 year29.5%5.4 (3.0 to 12.0)19.0%1.0 (0.5 to 3.0)
    ≥1 year70.5%6.7 (3.1 to 14.0)81.0%1.1 (0.5 to 3.3)
BMI (kg/m2)
    <2013.1%6.0 (3.0 to 15.2)40.0%1.0 (0.4 to 3.4)
    20 to 29.971.0%6.0 (3.0 to 13.0)58.8%1.1 (0.6 to 3.0)
    ≥ 3015.9%7.4 (4.0 to 15.0)1.2%4.1 (1.6 to 7.0)
Baseline vascular access
    fistula70.9%5.9 (3.0 to 13.0)91.1%1.0 (0.5 to 3.0)
    graft7.8%7.0 (3.0 to 12.0)6.9%1.7 (0.7 to 4.0)
    catheter21.2%8.0 (4.0 to 18.2)2.0%1.6 (0.7 to 3.4)
Coronary heart disease
    no49.1%5.3 (3.0 to 12.0)56.8%1.0 (0.5 to 3.0)
    yes50.9%7.0 (3.5 to 16.1)43.2%1.5 (0.6 to 4.0)
Cancer (other than skin)
    no84.5%6.0 (3.0 to 13.4)88.9%1.0 (0.5 to 3.0)
    yes15.5%7.0 (3.1 to 15.7)11.1%2.0 (0.6 to 6.5)
Other cardiovascular disease
    no56.8%5.5 (3.0 to 12.5)67.3%1.0 (0.5 to 3.0)
    yes43.2%7.0 (3.5 to 16.3)32.7%1.5 (0.6 to 4.0)
Cerebrovascular disease
    no80.9%6.0 (3.0 to 13.0)85.4%1.0 (0.5 to 3.0)
    yes19.1%8.0 (3.3 to 17.0)14.6%1.7 (0.6 to 4.0)
Congestive heart failure
    no55.7%5.8 (3.0 to 12.0)72.8%1.0 (0.5 to 3.0)
    yes44.3%7.0 (3.3 to 17.0)27.2%1.8 (0.7 to 4.1)
Diabetes
    no65.0%6.0 (3.0 to 13.0)62.4%1.0 (0.5 to 3.0)
    yes35.0%7.0 (3.1 to 15.0)37.6%1.2 (0.6 to 3.6)
Hypertension
    no17.9%6.4 (4.0 to 14.0)23.2%1.0 (0.5 to 3.6)
    yes82.1%6.0 (3.0 to 14.0)76.8%1.0 (0.5 to 3.0)
Neurologic disease
    no88.2%6.0 (3.0 to 13.0)89.9%1.0 (0.5 to 3.0)
    yes11.8%7.3 (3.0 to 18.2)10.1%2.2 (0.8 to 6.1)
Psychiatric disorder
    no87.8%6.0 (3.0 to 13.0)96.0%1.0 (0.5 to 3.1)
    yes12.2%7.0 (3.0 to 18.0)4.0%1.6 (0.5 to 5.4)
Peripheral vascular disease
    no66.5%5.6 (3.0 to 12.0)79.9%1.0 (0.5 to 3.0)
    yes33.5%8.0 (4.0 to 18.0)20.1%2.0 (1.0 to 5.4)
Albumin (g/dl)
    <3.526.4%10.0 (5.0 to 28.0)16.7%2.3 (1.0 to 10.0)
    3.5 to 3.941.5%6.5 (3.0 to 13.0)45.9%1.2 (0.6 to 3.2)
    ≥4.032.2%5.0 (2.4 to 10.0)37.4%1.0 (0.3 to 2.0)
Ferritin (ng/ml)
    <50064.3%5.1 (3.0 to 11.5)92.8%1.0 (0.5 to 3.0)
    500 to 79921.3%7.0 (3.3 to 17.6)4.4%2.0 (1.0 to 5.3)
    ≥ 80014.4%10.0 (4.2 to 26.0)2.9%2.3 (1.0 to 8.9)
WBC count (×103 cells/dl)
    <8.069.3%5.0 (3.0 to 11.2)85.8%1.0 (0.5 to 3.0)
    8.0 to 10.924.3%8.0 (4.0 to 18.6)12.6%3.0 (1.0 to 10.5)
    ≥11.06.4%15.6 (6.0 to 40.0)1.6%5.0 (2.1 to 15.2)
  • ANZ, Australia-New Zealand; CRP, C-reactive protein; IQR, interquartile range; WBC, white blood cell; BMI, body mass index.

  • a Among patients with non-missing CRP values. Missing values <10% except for the following: BMI in Europe/ANZ (10.6%), albumin in Europe/ANZ (11.3%), and ferritin in Japan (24.5%).

  • b Nonparametric tests on the median scores tested the associations between patient characteristics and CRP within each region. P < 0.01 for all except in Europe/ANZ, cancer (0.08), hypertension (0.26), neurologic disease (0.13), psychiatric disorder (0.39); in Japan, time on ESRD (0.08), baseline vascular access (0.19), diabetes (0.02), hypertension (0.40), psychiatric disorder (0.41), and ferritin (0.04).